Skip to main content
GoodMoatv1.3
Sign in
JUNS logo

JUNS

CompareEarnings: Aug 31, 2026

Jupiter Neurosciences Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Current Price

$0.24

+16.93%
Profile
Valuation (TTM)
Market Cap$7.06M
P/E-0.77
EV—
P/B—
Shares Out29.44M
P/Sales174.48
Revenue$40448.00
EV/EBITDA—

Jupiter Neurosciences Inc (JUNS) Company Profile

JUNS Company Information

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging.

The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line.

Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability.

Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function.

The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

Florida, USA

JUNS Key Officers

Key officers data coming soon

JUNS Company Profile

Jupiter Neurosciences Inc (JUNS) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in Florida, USA.

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Market cap is $7.06M. There are 29.4M shares outstanding.

See the full Jupiter Neurosciences Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if JUNS is a good investment.